BACKGROUND:Tenofovir disoproxil fumarate (TDF), a prodrug of tenofovir (TFV), may be ideal for topical HIV preexposure prophylaxis because it has higher tissue and cell permeability than TFV; is not adversely impacted by seminal proteins; and its active metabolite, TFV-diphosphate (TFV-DP), has a long intracellular half-life. We engineered a TDF eluting polyurethane reservoir intravaginal ring (IVR) to provide near constant mucosal antiretroviral concentrations. METHODS: A first-in-human randomized placebo-controlled trial was conducted to assess the safety and pharmacokinetics of the TDF IVR in healthy, sexually abstinent women (15 TDF and 15 placebo). Drug concentrations were measured in cervicovaginal fluid (CVF) obtained by swab, cervical tissue, plasma, and dried blood spots (DBS) over 14 days of continuous ring use. RESULTS: There were 43 total, 23 reproductive tract, and eight product-related grade 1 adverse events. Steady-state CVF TFV concentrations were achieved proximal (vagina, ectocervix) and distal (introitus) to the TDF IVR 1 day after ring insertion. Median tissue TFV-DP concentrations 14 days after TDF IVR placement were 120 fmol/mg (interquartile range 90, 550). CVF collected from the cervix 1 week and 2 weeks after TDF IVR insertion provided significant protection against ex-vivo HIV challenge. Eleven of 14 (78%) participants had detectable TFV-DP DBS concentrations 14 days after TDF IVR placement, suggesting that DBS may provide a surrogate marker of adherence in future clinical trials. CONCLUSION: A TDF IVR is safe, well tolerated, and results in mucosal TFV concentrations that exceed those associated with HIV protection. The findings support further clinical evaluation of this TDF IVR.
RCT Entities:
BACKGROUND:Tenofovir disoproxil fumarate (TDF), a prodrug of tenofovir (TFV), may be ideal for topical HIV preexposure prophylaxis because it has higher tissue and cell permeability than TFV; is not adversely impacted by seminal proteins; and its active metabolite, TFV-diphosphate (TFV-DP), has a long intracellular half-life. We engineered a TDF eluting polyurethane reservoir intravaginal ring (IVR) to provide near constant mucosal antiretroviral concentrations. METHODS: A first-in-human randomized placebo-controlled trial was conducted to assess the safety and pharmacokinetics of the TDF IVR in healthy, sexually abstinent women (15 TDF and 15 placebo). Drug concentrations were measured in cervicovaginal fluid (CVF) obtained by swab, cervical tissue, plasma, and dried blood spots (DBS) over 14 days of continuous ring use. RESULTS: There were 43 total, 23 reproductive tract, and eight product-related grade 1 adverse events. Steady-state CVF TFV concentrations were achieved proximal (vagina, ectocervix) and distal (introitus) to the TDF IVR 1 day after ring insertion. Median tissue TFV-DP concentrations 14 days after TDF IVR placement were 120 fmol/mg (interquartile range 90, 550). CVF collected from the cervix 1 week and 2 weeks after TDF IVR insertion provided significant protection against ex-vivo HIV challenge. Eleven of 14 (78%) participants had detectable TFV-DPDBS concentrations 14 days after TDF IVR placement, suggesting that DBS may provide a surrogate marker of adherence in future clinical trials. CONCLUSION: A TDF IVR is safe, well tolerated, and results in mucosal TFV concentrations that exceed those associated with HIV protection. The findings support further clinical evaluation of this TDF IVR.
Authors: Elizabeth T Montgomery; A van der Straten; H Cheng; L Wegner; G Masenga; C von Mollendorf; L Bekker; S Ganesh; K Young; J Romano; A Nel; C Woodsong Journal: AIDS Behav Date: 2012-10
Authors: John A Moss; Marc M Baum; Amanda M Malone; Sean Kennedy; Etana Kopin; Cali Nguyen; Josh Gilman; Irina Butkyavichene; Robyn A Willis; Kathleen L Vincent; Massoud Motamedi; Thomas J Smith Journal: AIDS Date: 2012-03-27 Impact factor: 4.177
Authors: Pedro M M Mesquita; Rachna Rastogi; Theodore J Segarra; Ryan S Teller; N Merna Torres; Ashley M Huber; Patrick F Kiser; Betsy C Herold Journal: J Antimicrob Chemother Date: 2012-03-30 Impact factor: 5.790
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Andrea Ries Thurman; Thomas Kimble; Betsy Herold; Pedro M M Mesquita; Raina N Fichorova; Hassan Y Dawood; Titilayo Fashemi; Neelima Chandra; Lorna Rabe; Tina D Cunningham; Sharon Anderson; Jill Schwartz; Gustavo Doncel Journal: AIDS Res Hum Retroviruses Date: 2015-07-23 Impact factor: 2.205
Authors: Sujatha Srinivasan; Noah G Hoffman; Martin T Morgan; Frederick A Matsen; Tina L Fiedler; Robert W Hall; Frederick J Ross; Connor O McCoy; Roger Bumgarner; Jeanne M Marrazzo; David N Fredricks Journal: PLoS One Date: 2012-06-18 Impact factor: 3.240
Authors: Marla J Keller; Lianna Wood; James M Billingsley; Laurie L Ray; Jessica Goymer; Shada Sinclair; Aileen P McGinn; Mark A Marzinke; Bruce Frank; Sujatha Srinivasan; Congzhou Liu; Jessica M Atrio; Lilia Espinoza; Nelly Mugo; Hans M L Spiegel; Peter L Anderson; David N Fredricks; Craig W Hendrix; Jeanne Marrazzo; Steven E Bosinger; Betsy C Herold Journal: Lancet HIV Date: 2019-07-15 Impact factor: 12.767
Authors: John W McBride; Nicola Dias; David Cameron; Robin E Offord; Oliver Hartley; Peter Boyd; Vicky L Kett; R Karl Malcolm Journal: Antimicrob Agents Chemother Date: 2017-09-22 Impact factor: 5.191
Authors: Sigcinile Dlamini; Michael Kuipa; Kim Enfield; Salndave Skosana; John G Woodland; Johnson Mosoko Moliki; Alexis J Bick; Zephne van der Spuy; Michelle F Maritz; Chanel Avenant; Janet P Hapgood Journal: Antimicrob Agents Chemother Date: 2019-12-20 Impact factor: 5.191
Authors: Randy M Stalter; Jenae Tharaldson; Derek H Owen; Eunice Okumu; Thomas Moench; Natasha Mack; Elizabeth E Tolley; Kathleen M MacQueen Journal: PLoS One Date: 2017-07-14 Impact factor: 3.240
Authors: Kathleen Listiak Vincent; John A Moss; Mark A Marzinke; Craig W Hendrix; Peter A Anton; Manjula Gunawardana; Lauren N Dawson; Trevelyn J Olive; Richard B Pyles; Marc M Baum Journal: PLoS One Date: 2018-08-22 Impact factor: 3.240
Authors: Kathleen L Vincent; John A Moss; Mark A Marzinke; Craig W Hendrix; Peter A Anton; Richard B Pyles; Kate M Guthrie; Lauren Dawson; Trevelyn J Olive; Irina Butkyavichene; Scott A Churchman; John M Cortez; Rob Fanter; Manjula Gunawardana; Christine S Miller; Flora Yang; Rochelle K Rosen; Sara E Vargas; Marc M Baum Journal: PLoS Med Date: 2018-09-28 Impact factor: 11.069
Authors: Randy M Stalter; Thomas R Moench; Kathleen M MacQueen; Elizabeth E Tolley; Derek H Owen Journal: J Int AIDS Soc Date: 2016-05-02 Impact factor: 5.396